Biganib 90 mg (Tablet)

Title

• Biganib

Categories

• Anti-cancer Medication
• Prescription Drug
• Oncology Drug

Description

• Indicated for ALK-positive metastatic Non-small cell lung cancer (NSCLC)
• A tyrosine kinase inhibitor targeting ALK, ROS1, IGF-1R, FLT-3, EGFR
• Pharmacokinetics including absorption, distribution, metabolism, and excretion
• Recommended dosing regimen
• Drug interactions with CYP3A inhibitors and inducers
• Contraindications
• List of side effects such as ILD, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hyperglycemia
• Guidance for pregnancy, lactation, and reproductive potential
• Precautions for ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK and pancreatic enzyme elevation, hyperglycemia
• Therapeutic class as cytotoxic chemotherapy
• Storage conditions

Dimensions

• Tablets

Color Options

• N/A

Functions

• Treatment of ALK-positive NSCLC
• Inhibition of kinases including ALK, ROS1, IGF-1R, FLT-3, EGFR

Materials

• Active Ingredient: Brigatinib

Technical Specifications

• Absorption range: 30 to 240 mg
• Median time to peak concentration: 1 to 4 hours
• Volume of distribution at steady-state: 153 L
• Apparent oral clearance at steady-state: 12.7 L/h
• Plasma elimination half-life: 25 hours
• Metabolism by CYP2C8 and CYP3A4

Design Elements

• Tablet form
• Oral administration
• Dosage regimen of 90 mg for the first 7 days, then 180 mg once daily

Usability Features

• May be taken with or without food
• Tablets should be swallowed whole
• If a dose is missed, do not take an additional dose

Indications

• Treatment of ALK-positive metastatic NSCLC who have progressed on or are intolerant to Crizotinib

Pharmacology

• Inhibition of ALK autophosphorylation and downstream signaling proteins
• Inhibition of EML4-ALK-positive NSCLC xenograft growth in mice
• Pharmacokinetic properties including absorption, distribution, metabolism, and excretion

Dosage & Administration

• Recommended dosing regimen
• Instructions for administration including swallowing tablets whole, not crushing or chewing

Interaction

• Drugs that may increase Biganib plasma concentrations
• Drugs that may decrease Biganib plasma concentrations
• Drugs that may have their plasma concentrations altered by Biganib

Contraindications

• Known hypersensitivity to Brigatinib or any other components

Side Effects

• List of potential side effects such as ILD, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hyperglycemia

Pregnancy & Lactation

• Guidance for pregnant women, lactating women, females reproductive potential, males reproductive potential, and infertility

Precautions & Warnings

• Precautions for ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK and pancreatic enzyme elevation, hyperglycemia

Therapeutic Class

• Cytotoxic Chemotherapy

Storage Conditions

• Keep below 30°C temperature
• Keep away from light & moisture
• Keep out of the reach of children

Related Brands

• Trepmac 90 mg (Tablet) - genvio-pharma-ltd